– A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks – – These data support the potential of PER-001 as the first disease-modifying treatment for glaucoma –  –PER-001 improved ocular blood flow, validating target engagement and the sustained release profile of PER-001, enabling a convenient […]

Study AER-01-002 is using a novel and precision imaging strategy to enroll 100 mucus plug-high chronic obstructive pulmonary disease (COPD) patients AER-01-002 is well powered to determine if 28-days of once daily dosing of fexlamose is safe and improves lung function Fexlamose has been shown in Phase 1 studies of 96 healthy volunteers to be […]

Financing accelerates MT-302, the Company’s first clinical candidate for in vivo cell programming, into a Phase 1/2 clinical trial for TROP2+ solid tumors CAMBRIDGE, Mass., May 18, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, announced today the completion of a $73 million financing led by Hatteras Investment Partners, with participation from […]

With the commercialization of Qvella technology for Positive Blood Culture (PBC) processing, healthcare facilities can now get results up to 24 hours faster than current methods   TORONTO & LISBON, Portugal–(BUSINESS WIRE)–Qvella, a diagnostics company that aims to reduce time to results in bacteriology, today announced the commercialization of its FAST™ System and FAST-PBC Prep […]

A new biotech startup with operations in Seattle and Durham, N.C., has launched with $40 million in new funding and a leadership team peppered with veterans of Seattle cell therapy biotechs. Tune Therapeutics is deploying technology to fine-tune the activity of genes in cells. The company has developed a proprietary platform called TEMPO that operates as […]

Industry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke MIAMI, June 23, 2021 (GLOBE NEWSWIRE) — RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced the closing of a $15 million Series A financing. The financing was led by […]

Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease Series A-2 led by Hatteras Venture Partners and Biohaven Donnie McGrath, M.D., and Seth Rudnick, M.D., join Artizan’s board of directors NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) — Artizan Biosciences, Inc. (“Artizan”), a […]

WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced the pricing of its upsized initial public offering of 8,684,800 common shares at a […]

  Financing will advance two ARC™ clinical programs and expand pipeline development —   DURHAM, NC and AUSTIN, TX – June 15, 2020 – Shattuck Labs, Inc. (“Shattuck”), a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform to develop a novel class of biologic medicines for the treatment of cancer and autoimmune […]

CAMBRIDGE, Mass., March 12, 2020 /PRNewswire/ — Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. The round was led by Biotechnology Value Fund (BVF) and Redmile Group with participation from Wellington Management Company, Bain Capital Life Sciences, funds managed […]

Experienced executive to lead corneal disease clinical program for TTHX1114  SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics today announced the appointment of Thomas M. Tremblay, RN, BSN to the newly created position of Vice President, Clinical Development. He brings to Trefoil more than 25 years of experience in pharmaceutical development across a variety of therapeutic areas. Trefoil Therapeutics appoints […]

— Acquisition to Expand Alkermes’ Presence in CNS to a Wide Range of Neurodegenerative Diseases Through Epigenetic Control of Synaptogenesis — DUBLIN, Ireland and BOSTON, Mass., Nov. 18, 2019 — Alkermes plc (Nasdaq: ALKS) and Rodin Therapeutics, Inc. (Rodin) today announced that they have entered into a definitive agreement under which Alkermes will acquire Rodin, a privately held biopharmaceutical company focused […]

Poised for Growth and Expansion of LifeFlow Throughout U.S. DURHAM, N.C., Oct. 22, 2019 /PRNewswire/ — 410 Medical, Inc., a medical device company developing innovative technologies for critical care, announced today it has closed on a Series A financing of $8 million led by Hatteras Venture Partners, with participation from OSF Healthcare and existing investors including Sovereign’s Capital. 410’s […]

Partnership will leverage Ribometrix’s discovery platform for up to three therapeutic programs Ribometrix to receive $20 million in upfront payment and Vertex equity investment; potential for additional milestones and royalty payments BOSTON, Mass. and DURHAM, N.C. – September 30, 2019 – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and RNA therapeutics developer Ribometrix, Inc. announced today that the […]

July 16, 2019 07:30 ET | Source: Trefoil Therapeutics     Lead candidate TTHX1114 will advance to IND and clinical study in corneal endothelial disease in early 2020 SAN DIEGO, July 16, 2019 (GLOBE NEWSWIRE) — Trefoil Therapeutics announced it raised $28 million in an oversubscribed Series A financing. The company is developing novel engineered fibroblast growth factor-1 proteins […]

BOSTON & CAMBRIDGE, Mass.–(BUSINESS WIRE)– -Multi-year collaboration leveraging Kymera’s proprietary targeted protein degradation platform to develop novel medicines- -Kymera to receive $70 million upfront, including equity investment, and potential additional milestone and royalty payments for up to six programs in the collaboration- Vertex Pharmaceuticals Incorporated (VRTX) and Kymera Therapeutics today announced that the two companies […]

ANN ARBOR, Mich., April 8, 2019 /PRNewswire/ — HistoSonics, developer of a non-invasive robotics platform and novel beam therapy, announced today that it has closed a $54 million Series C financing.  The round was led by Varian Medical Systems, Inc., the global leader in radiation therapy and oncology solutions, and included healthcare investors Johnson & Johnson Innovation – JJDC, Inc. (JJDC), […]

Redwood City, CA – February 5, 2019 – Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative therapies for ocular diseases, today announced that the Board of Directors has appointed Frédéric Guerard as Chief Executive Officer.  Mr. Guerard’s career in the pharmaceutical industry spans over 20 years and includes multiple leadership, strategic, and […]

Series B financing led by 6 Dimensions Capital, Bessemer Venture Partners, and Pfizer Ventures Financing to enable the advancement of lead program into clinical development and support the progression of additional programs Cambridge, Mass. (Nov. 13, 2018) – Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, announced today […]

July 09, 2018 — RESEARCH TRIANGLE PARK, N.C. (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive leadership roles to support the company’s continued growth. John Demaree joins the company as Chief Commercial Officer and Stillman Hanson has been named General Counsel.

March 07, 2018 — ALPHARETTA, Ga. (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the pricing of its underwritten public offering of 6,538,462 shares of its common stock at a price to the public of $13.00 per share.

Nov. 28, 2017 (GLOBE NEWSWIRE) — RESEARCH TRIANGLE PARK, N.C. — G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced a clinical trial collaboration with AstraZeneca to evaluate AstraZeneca’s epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso® (osimertinib) in combination with G1’s oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC).

June 7, 2017 (PRNEWSWIRE) —ANN ARBOR, MI  — HistoSonics, Inc., a venture-backed medical device company developing a new image-guided, robotically assisted, platform therapy that is non-invasive and non-thermal, announced two significant developments today.

March 21, 2017  — DURHAM, N.C. — Bivarus, a patient-centered analytics company working with healthcare organizations to measure and analyze the patient experience and employee engagement, announced today it raised $4 million in a Series B from existing investors. Hatteras Venture Partners led this latest financing round. Other participants in the round include Excelerate Health Ventures, Nashville-based NueCura Partners and Boston Millennia Partners.

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2016 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. a clinical-stage oncology company, announced today a clinical trial collaboration with Genentech, a member of the Roche Group. A Phase 2 clinical trial is expected to begin in the first half of 2017 and will evaluate the combination of Genentech’s immune checkpoint, anti-PD-L1 antibody Tecentriq® (atezolizumab) with G1’s CDK4/6 inhibitor trilaciclib (G1T28) as a first-line treatment for patients with small-cell lung cancer (SCLC) receiving chemotherapy.

ALPHARETTA, Ga., July 26, 2016 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today reports additional top-line data from its Phase 2 clinical trial (TANZANITE).

REDWOOD CITY, CA–(Marketwired – May 2, 2016) – Graybug Vision, a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced the closing of a $44.5 million Series B financing.

CARY, N.C.–(BUSINESS WIRE)–Medfusion, a leading provider of patient experience management (PXM) solutions, today announced it will debut the latest version of its mobile app, Medfusion Plus, at the Healthcare Information and Management Systems Society 2016 Annual Conference & Exhibition (HIMSS16). This latest product development supports the company’s initiative to empower patients by facilitating access to and transparency of their own health data through mobile devices.

ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced the closing of a $20 million Series C financing.

RESEARCH TRIANGLE PARK, NC, August 11, 2015 – G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that it has initiated two Phase 1b/2a trials of the CDK4/6 inhibitor G1T28 in patients with small-cell lung cancer (SCLC). G1T28 is an intravenous (IV) therapy being studied as a bone marrow and immune system chemoprotectant in patients with SCLC who are receiving chemotherapy.

NASHVILLE, Tenn.–(BUSINESS WIRE)–NuSirt Biopharma, a company dedicated to improving the lives of those with chronic metabolic diseases, announced it has raised $6 million in Series C financing, of which $2 million has been funded. Hatteras Venture Partners was joined by existing stockholders, including Mountain Group Partners and TriStar Technology Ventures.

RALEIGH, N.C., April 17, 2015 /PRNewswire/ — Contego Medical, the first and only provider of the Integrated Embolic Protection™ filter platform for angioplasty balloon and stent delivery catheters, announces the completion of a $5.6 million Series B financing round led by Hatteras Venture Partners, an early stage venture firm with a focus on medical devices, biopharmaceuticals, diagnostics and related opportunities in human medicine. The round also included Mountain Group Partners, Lookout Capital and Medical Mutual.

BOSTON – February 5, 2015 – ORIG3N, Inc., a pioneer in regenerative medicine and provider ofpluripotent stem cell storage, has raised $3.1 million in funding from an investor syndicate that includes Hatteras Venture Partners, Harris & Harris Group, KTB and Mountain Group Capital.

Alpharetta, Ga.–(BUSINESS WIRE)–Clearside Biomedical, Inc. today announced the eight-week ongoing observations in patients with non-infectious uveitis.

LAWRENCEVILLE, N.J., Aug. 19, 2014 (GLOBE NEWSWIRE) — via PRWEB – Edison Partners proudly announced today leading a $9 million growth financing of Clinverse, Inc. Based in Durham, NC, Clinverse is an emerging leader in clinical trial finance, automating millions of dollars in financial transactions for clinical trials across the globe. Edison’s $5 million investment will accelerate the company’s product roadmap, bolster infrastructure, and expand sales and marketing. Co-investors include Hatteras Venture Partners.

On April 9, Morrisville’s Clinipace Worldwide announced a partnership with Massachusetts pharmaceutical company Karyopharm Therapeutics (Nasdaq: KPTI), a development-stage company working primarily on cancer treatments. In this arrangement, Karyopharm chose Clinipace as a “preferred provider” in which Clinipace will manage several clinical programs, including oncology and wound healing.

Chapel Hill, NC, November 1, 2013 – G1 Therapeutics, Inc. today announced that it has been selected as a MAIN/Stage presenter at the 2013 Southeast BIO Investor & Partnering Forum to be held November 6-7 at the Jefferson Hotel in Richmond, Virginia. Christy Shaffer, Ph.D., Executive Chair of G1’s Board of Directors, will present to the audience of potential investors and partners on the afternoon of November 6. Jay Strum, Ph.D., President of G1, will also be in attendance.

WASHINGTON – Hatteras Venture Partners of Durham, N.C. is the first licensee in the Early Stage Innovation Funds initiative, a part of the U.S. Small Business Administration’s (SBA) Small Business Investment Company (SBIC) capital investment program.

ATLANTA and DURHAM – (Business Wire) – Ophthalmic startup Clearside Biomedical, Inc. and Hatteras Venture Partners announce today that they have launched the company with a $4,000,000 Series A venture financing to fund the initial development of Clearside Biomedical’s ocular microinjection platform and initial clinical testing of Clearside Biomedical’s lead product for Macular Edema and Retinal Vein Occlusion.

IRVINE, CALIFORNIA – Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced that it has completed the acquisition of Embrella Cardiovascular, Inc., the developer of the Embrella Embolic Deflector System, which can be used during transcatheter heart valve procedures. The purchase price was approximately $43 million cash, […]

By Catherine Hollingsworth, Staff Writer (BioWorld Today) – Viamet Pharmaceuticals Inc. signed a deal worth more than $200 million with the Novartis Option Fund to discover and develop metalloenzyme inhibitors of interest to the Swiss drugmaker. Morrisville, N.C.-based Viamet said the Novartis agreement provides an opportunity to expand its Metallophile technology beyond the current development […]

Wayne, PA – Embrella Cardiovascular, Inc., a private company developing the next generation of embolic order tramadol online overnight shipping protection devices for use during coronary procedures, today announced the final closing of its Series B financing round, raising a total of $6.7 million in new capital.

Nashville, TN – Pathfinder Therapeutics, Inc. (PTI), a medical device company focused on the development of “surgical GPS” systems for the abdomen, announced that it has closed on a $5.2 million Series A financing round led by Hatteras Venture Partners of Research Triangle Park, NC. Other investors included Florida Gulfshore Capital, Clayton & Associates, Nashville Capital Network, Lumira, and Vanderbilt University. Concurrent with the financing, Clay Thorp and Bob Morff, PhD, from Hatteras Venture Partners and Richard Molloy from Florida Gulfshore Capital have joined the Board of Pathfinder, and Bob will serve as interim CEO.

Research Triangle Park, NC – Clinipace, a clinical research software company based in the Research Triangle Park, announced today that it has closed a $2.6 million Series B financing round led by Hatteras Venture Partners, a life sciences focused venture firm based in Durham, NC, with participation by existing investors Brook Private Equity Advisors of Boston, MA and Emergent Growth Fund of Gainesville, FL.